A practical reference on Alpha-MSH: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
=== High Point Media === After Phillips sold his majority interest in EAS, he concentrated on his writing and on promotion of his books through his publishing company, High Point Media, as well as Value Creation, a branch of EAS. Body for Life hit bookstores in 1999, and by 2003 it had sold 3.5 million copies in 24 languages. The book topped the charts in 11 different countries-including the United States, England, Japan, Australia, Greece and Finland. In 2004 USA Today named it among the Top 15 bestselling books of the past decade. In November 2003, Eating for Life: Your Guide to Great Health, Fat Loss and Increased Energy! was released. In the book Phillips offers his plan "to help inspire and guide even more people to improve their health and lift their quality of life to new heights." In February 2006, Phillips announced his "Great American Transformation Experience" (GATE) with a goal to transform America's fitness from world's worst to first within 10 years. On June 21, 2010, Phillips' latest book, Transformation: The Mindset You Need. The Body You Want. The Life You Deserve was released. A companion website, Transformation.com, that walks individuals through the transformation process was also updated. The site features a community dedicated to supporting its members' personal goals. On July 10, 2010, the book made the New York Times Best Seller list.
The courts give the EU a wide discretion to implement policy, so judicial review is possible only if agricultural measures are 'manifestly inappropriate'. EU law does not yet have a systematic plan or subsidies to rewild depleted environments, and to move to complete clean energy infrastructure.
=== Signaling cascade === Gonadotropin releasing hormone (GnRH) is released by projections of the hypothalamus into the anterior pituitary gland. Gonadotrophs are stimulated to produce follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are released into the bloodstream to act upon the ovaries. Luteinizing hormone serves to directly stimulate theca cells. Together, these organs comprise the hypothalamic–pituitary–gonadal axis (HPG axis). Within the ovaries, the LH receptor (a G protein-coupled receptor) binds to LH in the bloodstream, and the signal is transduced to the interior of theca cells through the action of the second messenger cAMP and third messenger protein kinase A (PKA). Theca cells are then stimulated to produce the androgen, androstenedione, which is sent in a paracrine fashion to neighboring granulosa cells for conversion into estrone and eventually estradiol.
== Medical devices == A variety of medical devices are in use or under consideration for treatment of depression including devices that offer electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and cranial electrotherapy stimulation. The use of such devices in the United States requires approval by the U.S. Food and Drug Administration (FDA) after field trials. In 2010 an FDA advisory panel considered the question of how such field trials should be managed. Factors considered were whether drugs had been effective, how many different drugs had been tried, and what tolerance for suicides should be in field trials.
Sources: en.wikipedia.org
(2) The study of Raymond Damadian (New York Downstate Medical Center, 1971-1972): Inspired by Hazlewood and Chang's findings about cellular water relaxation time changes during muscle development, Damadian proposed that T1 is generally longer in tumors compared to normal tissues. He demonstrated this idea with a quick NMR measurement on rat tissues. Damadian also filed a patent in late 1972 for a full-body machine of using NMR to detect cancer. (3) The study of Paul Lauterbur (The State University of New York at Stony Brook, 1973): Lauterbur proposed to use a magnetic field gradient to conduct a 2-dimensional NMR scan. He called his method zeugmatography. For demonstration, he used CW NMR (not spin-echo) to image the proton spin density in an artificial sample consisting of two tubes of water. In the late 1970s, physicists Peter Mansfield at the University of Nottingham and Lauterbur developed MRI-related techniques, like the echo-planar imaging (EPI) technique. Raymond Damadian's work into nuclear magnetic resonance (NMR) has been incorporated into MRI, having built one of the first scanners. Advances in semiconductor technology were crucial to the development of practical MRI, which requires a large amount of computational power. This was made possible by the rapidly increasing number of transistors on a single integrated circuit chip. Mansfield and Lauterbur were awarded the 2003 Nobel Prize in Physiology or Medicine for their "discoveries concerning magnetic resonance imaging".
== Foreign relations == Throughout the period of its Unilateral Declaration of Independence (1965 to 1979), Rhodesia pursued a foreign policy of attempting to secure recognition as an independent country, and insisting that its political system would include 'gradual steps to majority rule.' Ardently anti-communist, Rhodesia tried to present itself to the West as a front-line state against communist expansion in Africa, to little avail. Rhodesia received little international recognition during its existence; recognition only occurred after elections in 1980 and a transition to majority rule. Rhodesia wished to retain its economic prosperity and also feared communist elements in the rebel forces, and thus felt their policy of a gradual progression to black majority rule was justified. However, the international community refused to accept this rationale, believing that their policies were perpetuating racism. This attitude was part of the larger decolonisation context, during which Western powers such as the United Kingdom, France, and Belgium hastened to grant independence to their colonies in Africa.
=== Foundations of modern chemistry === In 1774, Antoine Lavoisier used the reaction of water steam with metallic iron inside an incandescent iron tube to produce hydrogen in his experiments leading to the demonstration of the conservation of mass, which was instrumental in changing chemistry from a qualitative science to a quantitative one.
Another phenotype, Muscle-eye-brain disease (MEB) is the dystroglycanopathy most prevalent in Finland, and is caused by mutations in the POMGnT1, FKRP, FKTN, ISPD, and TMEM5 genes. The POMGnT1 gene is expressed in the same tissues as FKTN, and MEB appears to have a similar severity as FCMD. However, symptoms unique to MEB include glaucoma, atrophy of the optic nerves, and retinal generation. The least severe phenotype of dystroglycanopathies is CMD type 1c (MDC1C), caused by mutations in the FKRP and the LARGE gene, with a phenotype similar to MEB and WWS. MDC1C also includes Limb-Girdle muscular dystrophy.
=== Classification === Four commonly accepted criteria for classifying patients with MCTD have been published: the Sharp criteria (1987), the Alarcón-Segovia criteria (1987), the Kasukawa criteria (1987), and the Kahn criteria (1991). The Alarcon-Segovia and Kahn criteria have equivalent sensitivity and specificity, and a comparison of the four diagnostic criteria suggests that the Kasukawa criteria provide the best sensitivity, while both Alarcon-Segovia and Kahn criteria have the maximum specificity.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.